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BACKGROUND: Cancer patients often have pre-existing comorbidities, which can influence timeliness of cancer diagnosis. We
examined symptoms, investigations and emergency presentation (EP) risk among colorectal cancer (CRC) patients by comorbidity
status.
METHODS: Using linked cancer registration, primary care and hospital records of 4836 CRC patients (2011–2015), and multivariate
quantile and logistic regression, we examined variations in specialist investigations, diagnostic intervals and EP risk.
RESULTS: Among colon cancer patients, 46% had at least one pre-existing hospital-recorded comorbidity, most frequently
cardiovascular disease (CVD, 18%). Comorbid versus non-comorbid cancer patients more frequently had records of anaemia (43%
vs 38%), less frequently rectal bleeding/change in bowel habit (20% vs 27%), and longer intervals from symptom-to-first relevant
test (median 136 vs 74 days). Comorbid patients were less likely investigated with colonoscopy/sigmoidoscopy, independently of
symptoms (adjusted OR= 0.7[0.6, 0.9] for Charlson comorbidity score 1–2 and OR= 0.5 [0.4–0.7] for score 3+ versus 0. EP risk
increased with comorbidity score 0, 1, 2, 3+: 23%, 35%, 33%, 47%; adjusted OR= 1.8 [1.4, 2.2]; 1.7 [1.3, 2.3]; 3.0 [2.3, 4.0]) and for
patients with CVD (adjusted OR= 2.0 [1.5, 2.5]).
CONCLUSIONS: Comorbid individuals with as-yet-undiagnosed CRC often present with general rather than localising symptoms
and are less likely promptly investigated with colonoscopy/sigmoidoscopy. Comorbidity is a risk factor for diagnostic delay and has
potential, additionally to symptoms, as risk-stratifier for prioritising patients needing prompt assessment to reduce EP.
British Journal of Cancer; https://doi.org/10.1038/s41416-021-01603-7
BACKGROUND
Diagnosing colorectal cancer (CRC) at an early stage and before it
becomes a medical emergency is paramount for improving
survival, patient reported outcomes and disruptions to health
services [1–3]. Efforts to improve the timely diagnosis of cancer in
England have included the roll out of a population screening
programme since 2006, fast-track diagnostic pathways for patients
with symptoms suggestive of cancer and recommendations on
the use faecal immunochemical testing (FIT) in primary care for
patients with low-risk bowel symptoms to guide specialist referrals
[4–6]. In spite of improvements, large proportions of patients are
still diagnosed following an emergency admission and/or with late
stage disease, having substantially poorer outcomes than those
diagnosed through non-emergency routes and/or with early-stage
disease [3, 4]. In England 23% of CRC are diagnosed following an
emergency presentation, [3] with international figures ranging
between 11 and 39% [7]. Emergency diagnosis is associated with
advanced cancer stage and poorer survival, even after controlling
for stage [7]. One-year survival is 49% after emergency CRC
diagnosis compared to over 80% for non-emergency routes [3].
Emergency presentations are associated with worse patient-
reported outcomes, disruptions to hospital services [2, 8, 9] and
affect healthcare resource use [10]. Reducing emergency pre-
sentations is therefore considered a key public health target [1].
The relevance of pre-existing conditions (comorbidities) in
influencing the timely diagnosis of cancer and cancer outcomes
has been increasingly recognised [11–17]. The COVID-19 pan-
demic, during which many cancer investigations have been
postponed [18–20], with an expected 17% increase in CRC deaths,
[18] has highlighted the urgent need of identifying patient groups
at higher risk of diagnostic delays, such as those with non-specific
symptoms and/or comorbidities [19–21]. Previous research has
shown that many patients with comorbidities repeatedly present
to their doctor with cancer-related symptoms in the two years
before being diagnosed with cancer as an emergency [22].
However, little is known on how comorbidities may affect different
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aspects of the diagnostic process, such as presenting symptoms,
timeliness of investigations and length of diagnostic intervals [11].
To enhance risk-stratification approaches and improve diagnos-
tic timeliness and cancer outcomes, we need to understand likely
differences in symptomatic presentations and use of diagnostic
investigations by morbidity status. We aimed to evaluate the
association between pre-existing morbidities, and symptomatic
presentation, the use of diagnostic investigations and the risk of
emergency diagnosis among symptomatic patients subsequently
diagnosed with CRC. We focused on patients presenting with
possible cancer symptoms as they represent the great majority of
CRC cases (over 90%) and they have worse outcomes than
screening-detected individuals [3, 23, 24]. The ultimate aim is to
provide evidence for informing decision-making regarding refer-
rals/diagnostic investigations for symptomatic patients.
METHODS
Study population and data sources
We performed a cohort study on patients aged 18–99 years diagnosed
with colon cancer (International Classification of Diseases 10th Edition, ICD-
10, codes C18.1–C18.9) or rectal cancer (ICD-10 codes C19–C20) using
National Cancer Registry records, linked to primary care data from the
Clinical Practice Research Datalink (CPRD). The Cancer Registry includes all
cancers diagnosed in England, with excellent completeness and high
quality data [25]. CPRD has data for over 11 million patients from more
than 670 general practices across the United Kingdom [26] and is
representative of the general population [27]. It provides prospectively
collected patient-level information on signs/symptoms, diagnoses and
tests. In addition, we obtained individually linked secondary care records
from the Hospital Episode Statistics (HES) on outpatient and admitted
patient care. Information on the cancer site, date of diagnosis and age at
diagnosis was obtained from the linked National Cancer Registry. Data
linkage is carried out by the Trusted Third Party NHS Digital following high
standards [28].
To be included, patients had to be diagnosed between 2011 and 2015
and have at least one new-onset sign/symptom potentially related to CRC
(Supplementary code-list Box 1) recorded in primary care pre-cancer
diagnosis. We concentrated on new-onset symptoms, which are more
likely associated with an as-yet undiagnosed cancer, rather than chronic
symptoms, which are usually due to long-standing benign conditions (e.g.
diverticular disease or irritable bowel syndrome). New-onset symptoms
were defined as symptom recorded for the first time during the 2 years
pre-cancer diagnosis, with no prior record of the same symptom during
the 3–5 years pre-cancer.
As the study focused on symptomatic patients, we excluded patients
whose diagnostic route was classified as screening (Fig. 1a). The final study
sample comprised a total of 4836 cancer patients, which is in line with
expectations, considering that CPRD covers 7% of the population in
England [27].
Study variables
The main explanatory variables were comorbidities recorded in HES during
the 6 years before and up to the CRC diagnosis. We focused on hospital-
recorded comorbidities to provide evidence on the likely role played by
severe morbidities in influencing the use and timeliness of diagnostic
endoscopy, due to their possible impact on patients’ procedural risk. In
addition to examining the most common severe morbidities in hospita-
lised patients, we obtained two further measures of comorbidity burden,
the Charlson comorbidity score and the count of morbidities. Using a
validated algorithm [29], we identified morbidities through ICD-10 codes
within HES in-patient and out-patient records and selected the 17
conditions typically included in the Charlson score (Box 1). We used the
Charlson score as the main measure of comorbidity burden, as it is likely to
better reflect the assessment of procedural risk than the morbidity count.
Further explanatory variables were red flag symptoms/signs recorded in
primary care pre-cancer diagnosis, including CRC-localising symptoms
(rectal bleeding or change in bowel habit) and non-localising signs
(laboratory-confirmed anaemia); we also examined non-red flag symptoms
potentially related to CRC (including abdominal pain, constipation,
diarrhoea, weight loss and fatigue) [30, 31]. Classification in red flag or
non-red flag symptoms follows the UK NICE guidelines for suspected
cancer recognition and referral [31]. Change in bowel habit, as well as
rectal bleeding or unexplained anaemia, are considered red flag
symptoms, which warrant urgent referral for investigations, as they have
a Positive Predictive Value (PPV) >3% for colorectal cancer. Other
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Fig. 1 Study population, data sources and diagnostic intervals from symptomatic presentation to cancer diagnosis. a Study population
and data sources. b Diagnostic intervals from symptomatic primary care presentation to cancer diagnosis.
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symptoms, such as diarrhea, constipation or abdominal pain are associated
with a lower PPV for colorectal cancer and are not considered as red flag
symptoms based on NICE guidelines. While the terms ‘diarrhea’ or
‘constipation’ can be considered as deviations from normal bowel patterns,
the term ‘change in bowel habit’ is typically used in UK primary care
records when there is a higher suspicion of CRC, as it warrants urgent
referral according to NICE guidelines.
Relevant symptoms/signs (and related Medcodes/Readcodes) have been
defined based on the literature, guidelines [31] and clinical expert revisions
and classified in new-onset symptoms, if recorded for the first time during
the 2 years pre-cancer diagnosis, with no prior record of the same
symptoms 3–5 years prior. Anaemia was defined based on haemoglobin-
tests with values below the normal gender-specific range provided by
CPRD. Socio-demographic characteristics included gender, age and
deprivation (Index of Multiple Deprivation for England). Information on
TNM grouping stage at diagnosis was available from the linked National
Cancer Registry.
Information on diagnostic investigations was extracted from in-patient
and out-patient HES records in the 2 years pre-cancer diagnoses using
OPCS 4.5 Standard Classification for NHS procedures codes (Supplemen-
tary code-list Box 2). Investigations were classified as colonoscopy/flexible
sigmoidoscopy and non-specific abdominal/pelvic tests (abdominal
ultrasound, abdominal CT/MRI, gastroscopy, small bowel endoscopy,
gynaecologic tests, pelvic MRI/CT and pelvic ultrasound). To be included
in the analysis, investigations must have occurred following a CRC-relevant
symptom recorded in primary care. Investigations, such as chest x-rays or
cardiac tests, which might have been requested for other reasons (e.g.
respiratory or cardiac symptoms) were excluded a priori to minimise bias.
We calculated the ‘symptom-to-test’ interval as the time (in days) from
the first new-onset symptom recorded in primary care during the
24 months pre-cancer diagnosis to the first HES-recorded investigation.
The date of the first relevant symptom recording typically corresponds to
the primary care consultation date, as CPRD includes prospectively
collected information on symptoms recorded at the time of consultation.
The ‘test-to-diagnosis’ interval was the time from the first investigation to
cancer diagnosis. We also estimated the ‘overall symptom-to-diagnosis’
interval from the first new-onset relevant symptom during the 24 months
pre-cancer to cancer diagnosis (Fig. 1b). The date of diagnosis was based
on the data provided by the National Cancer Registry, which follows the
rules of the European Network of Cancer Registries [25].
Additionally, we performed sensitivity analyses focusing only on the
timing of bowel endoscopy (independently if this was the first test), as this
is very well documented in HES [12, 32]. Previous validation studies have
shown 96% accuracy for routine data on investigations collected in HES
[32, 33]. This sensitivity analysis excluded 1398 patients without evidence
of colonoscopy/sigmoidoscopy and focused on the 3436 patients with
lower GI endoscopy, among which 73% had an endoscopy as the first and
only investigation, 18% as first investigation followed by other tests and
9% as second investigation preceded by non-specific abdominal/
pelvic tests.
Information on emergency cancer diagnosis was derived from the linked
Cancer Registry and defined according to the Routes to Diagnosis
algorithm (Box 2), i.e. diagnosis following presentation to Accident and
Emergency, GP emergency referrals, or emergency pathways for in/out-
patients [3, 23].
Statistical analysis
Initially we described socio-demographic and clinical characteristics of
patients, including comorbidities, symptoms, type of investigations, stage
at diagnosis, and emergency presentation status. We used Chi-squared
tests to compare the distribution of socio-demographic and clinical
characteristics by comorbidity status.
We then performed two multivariable analyses. In the first, we employed
quantile multivariate regression to assess the variation in diagnostic
intervals (time intervals between symptomatic presentation in primary care
and the use of relevant diagnostic investigations) by comorbidity and
symptoms, accounting for age, sex and deprivation. Quantile regression is
an extension of linear regression for skewed data and is a well-established
approach for examining variation in time intervals to test, diagnosis or
treatment all of which are known to be right-skewed [34–37]. It allowed us
to compare diagnostic intervals by comorbidity status and other patient
characteristics at different centiles (50, 75 and 90) of the diagnostic
intervals. We focused on the median (50th centile) and 75th centile. The
final quantile regression model for each diagnostic interval included
variables a priori deemed relevant for interval length, based on the
literature and clinical reasoning (morbidities, symptoms, socio-
demographic factors). We focused on the interval length and used
quantile regression, rather than hazard models, as interval length is a more
intuitive outcome in this study: expressing how each variable affects the
interval(s) in absolute terms is preferable from a clinical and public health
perspective, rather than reporting the findings in relative terms, as would
be the case with hazard models.
In the second analysis, we used multivariable logistic regression to
assess the risk of emergency cancer diagnosis by comorbidity burden/
status, accounting for symptoms, type of first investigation and socio-
demographic characteristics. The final model encompassed all variables
thought a priori to be potentially relevant in influencing the risk of
emergency presentations based on the literature and clinical reasoning.
We also examined associations between the likelihood of having a
colonoscopy/flexible sigmoidoscopy as first investigation and comorbidity
burden/status, symptoms and socio-demographic characteristics.
As general practices can vary substantially, for example in their level of
use of investigations such as endoscopies [38–40], the analyses accounted
for patient clustering by practice and estimated robust standard errors. The
multivariable models did not include variables potentially on the causal
pathway (mediators): diagnostic route and type of first investigation, as
they might be between comorbidity, symptomatic presentation, and
length of diagnostic intervals (for example, colonoscopy is diagnostic in
most cases [41]); stage at diagnosis, as it might be on the causal pathway
between comorbidity and emergency presentation. Furthermore, to
reduce possible bias, we used different multivariable models, each with
a different morbidity measure (Charlson score, morbidity count, specific
morbidity variables), as these variables were a priori highly correlated by
construction, i.e. one is partly embedded in another. Finally, to assess how
the odds ratios change when accounting for covariates, we additionally
present the findings from the unadjusted models, as well as of the models
including only socio-demographic factors, followed by comorbidities, then
symptoms and investigations. We used Stata 15 for all statistical analyses.
Box 1. Comorbidities included in the study (following the Charlson











Diabetes without chronic complications
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Box 2. Routes to diagnosis for symptomatic patients included in the
study (based on NCIN-PHE) [23, 66]
Emergency cancer diagnosis
Diagnosis of cancer following presentation to an Accident and Emergency Unit
or a GP emergency referral or emergency pathways for in/out-patients.
Non-emergency cancer diagnoses
Two-week wait referrals: Patients referred urgently by their GP for suspected
cancer, so that they can see a specialist within 2 weeks (introduced in England
in 2000).
Routine GP referrals: Patients referred by their GP but not under the two-week
wait referral route.
Elective outpatient/inpatient: An elective route starting with an outpatient
appointment, either consultant to consultant referral or other referral; or starting
with inpatient admission where no earlier information is available from waiting
list prior to admission.
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RESULTS
Among the 3,215 symptomatic colon and 1621 rectal cancer
patients, approximately 46% and 36%, respectively, had at least
one morbidity recorded in HES during the 6 years pre-cancer
diagnosis, while 20% and 14%, respectively, had two or more
morbidities (multimorbidity) (Table 1). The most common
morbidities, included cardiovascular (CVD), chronic obstructive
pulmonary disease (COPD) and diabetes, both among colon (18%,
17%, 15%, respectively) and rectal cancer patients (13%, 13%,
12%, respectively).
Overall, 64% of colon and 81% of rectal cancer patients had at
least one red flag sign/symptom (anaemia, rectal bleeding or
change in bowel habit) recorded in the two years pre-cancer
diagnosis; 36 and 19% had non-red flag relevant symptoms only
(including abdominal pain, weight loss, fatigue). The single most
common relevant sign/symptom was lab-based anaemia in colon
cancer (40%) and rectal bleeding in rectal cancer patients (46%).
A colonoscopy or flexible sigmoidoscopy was performed as first
test to investigate relevant symptoms in 53% of colon and 79% of
rectal cancer patients. In a small proportion of patients (11 and
6%, respectively) a colonoscopy/sigmoidoscopy followed non-
specific abdominal/pelvic tests. Overall, the most frequent route to
cancer diagnosis was the urgent 2-week wait (TWW) referral, but
emergency diagnoses occurred in 30% of colon and 11% of rectal
cancer patients. Information on stage at diagnosis was available
for 78% of patients and, among them, stage IV disease accounted
for 31% of colon and 24% of rectal cancers (Table 1).
Comparison of patient characteristics, investigation use and
diagnostic route by comorbidity burden/status
Patients with at least one hospital-recorded comorbidity, com-
pared to those without, tended to be older and more deprived;
they more frequently had a record of anaemia and less frequently
rectal bleeding or change in bowel habit (Table 1). Similarly,
patients with the most common specific morbidities (CVD, COPD,
diabetes), versus patients without such conditions, more fre-
quently had records of anaemia and less frequently rectal
bleeding or change in bowel habit. This was particularly marked
among rectal cancer patients, where anaemia was recorded in
31% of CVD patients, 28% in COPD and 26% in diabetic patients,
versus 15% in patients without any of these conditions;
conversely, rectal bleeding/change in bowel habit was recorded
in 49% of CVD patients, 49% of COPD and 51% of diabetic
patients, versus 66% of patients without any such conditions (p <
0.001). A haemoglobin-test was performed more frequently in
comorbid versus non-comorbid patients during the 24 months
pre-cancer diagnosis (colon cancer: 93% versus 88%; rectal cancer:
91% versus 82%). In those who were tested, anaemia prevalence
in the 24 months pre-cancer was higher in comorbid versus non-
comorbid patients (colon cancer: 52% versus 48%; rectal cancer:
36% versus 22%).
Examining the type of first abdominal/pelvic investigation used
after patients presented with CRC-relevant symptoms shows that
colonoscopy/sigmoidoscopy was used less frequently in comorbid
versus non-comorbid patients (colon cancer: 47% versus 59%;
rectal cancer: 72% versus 83%). This was confirmed at multi-
variable analyses accounting for symptoms and patient character-
istics: the likelihood of being investigated with a colonoscopy/
flexible sigmoidoscopy was significantly lower for patients with
Charlson comorbidity score 1, 2, 3+ versus 0 (adjusted (a)OR= 0.7
[95% CI 0.6–0.9]; 0.7 [0.6–0.9]; 0.5 [0.4–0.7], respectively); there was
no variation by type of endoscopy, i.e. having a comorbidity was
associated with a lower likelihood of colonoscopy, as well as of
sigmoidoscopy as first test (data not shown). Examining the most
common specific morbidities showed similar findings, for example
among colon cancer patients, the likelihood of endoscopy was
lower for patients with versus without CVD (44% versus 55%;
aOR=0.7 [95% CI 0.6–0.9] and for those with versus without renal
disease (38% versus 54%; aOR=0.7 [95% CI 0.5–0.9].
Comorbid versus non-comorbid patients with CRC-related
symptoms were diagnosed more frequently with cancer through
the emergency route (colon cancer: 37% versus 23%; rectal cancer:
19% versus 7%, respectively) and less frequently through the
expedited two-week wait route (Table 1). Similarly, patients with
CVD or with chronic renal disease were more frequently
diagnosed with colon cancer through the emergency route
compared to those without these conditions (CVD: 43% versus
27%; renal disease: 45% versus 29%).
Association between patient characteristics, symptoms,
comorbidity burden/status and length of diagnostic intervals
The symptom-to-test, test-to-diagnosis and overall symptom-to-
diagnosis intervals were notably longer for comorbid versus non-
comorbid patients: median 136 versus 74 days; 20 versus 5 days;
and 266 versus 111 days, respectively, among colon cancer
patients (Fig. 2 and Table 2; Supplementary Tables 1–2;
Supplementary Fig. 1). Further, diagnostic intervals increased with
increasing comorbidity burden (Fig. 2 and Supplementary Table 2)
and were longer in patients with the most common individual
morbidities compared to those without such morbidities: e.g. the
longest symptom-to-test, test-to-diagnosis and overall symptom-
to-diagnosis intervals were observed for patients with chronic
renal disease versus those without: median 201 versus 88 days; 38
versus 10 days; 432 versus 151 days, respectively, among colon
cancer patients; and for patients with diabetes versus those
without: median 188 versus 85 days; 17 versus 10 days; 344 versus
140 days, respectively (Supplementary Table 3).
The multivariable quantile regression analysis showed that
increasing comorbidity burden was associated with a significantly
longer symptom-to-test interval: for example, for colon cancer
patients with Charlson comorbidity score of 2, the adjusted
median interval was 120 days [95% CI 40.6; 199.2] versus 30 days
[95% CI 1.7; 44.7] among non-comorbid patients with similar
symptoms and socio-demographic characteristics (Table 2). Older
age and female gender (for colon and rectal cancer, respectively)
were also associated with longer intervals, as were anaemia and
non red-flag presenting symptoms versus rectal bleeding/change
in bowel habit. Similar findings were observed for test-to-
diagnosis and symptom-to-diagnosis intervals (Supplementary
Tables 1–2).
Sensitivity analyses focusing on patients who underwent bowel
endoscopy, irrespective of whether it was the first investigation or
rather preceded by other non-specific abdominal/pelvic ultra-
sound scan, CT or MRI, showed similar findings, with a median
symptom-to-endoscopy interval of 179 versus 85 days for
comorbid versus non-comorbid patients and significantly longer
intervals with increasing Charlson score (Supplementary Table 4).
Risk of emergency cancer diagnosis by patient characteristics,
symptoms, comorbidity burden/status and type of diagnostic
investigation
Among colon cancer patients, the proportion of emergency
diagnosis increased with increasing Charlson comorbidity score
(23%, 35%, 33%, 47% for scores 0, 1, 2, 3+; adjusted (a)OR (vs 0
morbidities)= 1.8 [1.4, 2.2]; 1.7 [1.3, 2.3]; 3.0 [2.3, 4.0]) (Fig. 3 and
Supplementary Table 5). The risk of emergency diagnosis was
particularly high for patients with common morbidities, such as
CVD (43%, aOR= 2.0 [1.5–2.5], and for those with chronic renal
disease (44%, aOR= 1.5 [1.0–2.1] (Table 3).
Patients initially investigated with non-specific abdominal tests
(28%; aOR= 2.0 [1.6,2.6]) or without relevant investigations (62%;
aOR= 8.3 [6.7, 10.4]) also had a higher risk of emergency
diagnosis, compared to those with a colonoscopy/sigmoidoscopy
as first test (13%). Having only non red-flag symptoms versus
having either rectal bleeding or change in bowel habit increased
S.B. Majano et al.
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Table 1. Patient characteristics, diagnostic investigations and routes to cancer diagnosis by comorbidity status.
Colon Rectum






Age group <0.001 <0.001
<45 83 (2.6) 71 (4.1) 12 (0.8) 48 (3.0) 44 (4.2) 4 (0.7)
45–54 235 (7.3) 182 (10.5) 53 (3.6) 173 (10.7) 150 (14.4) 23 (4.0)
55–64 479 (14.9) 320 (18.5) 159 (10.7) 327 (20.2) 248 (23.9) 79 (13.6)
65–74 762 (23.7) 433 (25.0) 329 (22.2) 422 (26.0) 277 (26.7) 145 (24.9)
75–84 1144 (35.6) 513 (29.7) 631 (42.5) 473 (29.2) 251 (24.2) 222 (38.1)
85+ 512 (15.9) 211 (12.2) 301 (20.3) 178 (11.0) 69 (6.6) 109 (18.7)
Sex 0.132 0.131
Male 1569 (48.8) 823 (47.6) 746 (50.2) 974 (60.1) 610 (58.7) 364 (62.5)
Female 1646 (51.2) 907 (52.4) 739 (49.8) 647 (39.9) 429 (41.3) 218 (37.5)
Deprivation quintile <0.001 0.008
1 (Least deprived) 808 (25.1) 457 (26.4) 351 (23.6) 379 (23.4) 258 (24.8) 121 (20.8)
2 745 (23.2) 406 (23.5) 339 (22.8) 348 (21.5) 220 (21.2) 128 (22.0)
3 684 (21.3) 395 (22.8) 289 (19.5) 362 (22.3) 242 (23.3) 120 (20.6)
4 557 (17.3) 286 (16.5) 271 (18.2) 283 (17.5) 183 (17.6) 100 (17.2)
5 (most deprived) 421 (13.1) 186 (10.8) 235 (15.8) 249 (15.4) 136 (13.1) 113 (19.4)
New-onset symptoms in the two years before CRC diagnosis
Rectal bleeding
or CIBH
767 (23.9) 465 (26.9) 302 (20.3) <0.001 1034 (63.8) 730 (70.3) 304 (52.2) <0.001
Anaemia (Lab-
based)
1285 (40.0) 650 (37.6) 635 (42.8) 272 (16.8) 122 (11.7) 150 (25.8)
Non red-flag
symptoms
1163 (36.2) 615 (35.5) 548 (36.9) 315 (19.4) 187 (18.0) 128 (22.0)
Had Colonoscopy/Flexible Sigmoidoscopy two years before CRC diagnosis <0.001 0.013
No 1143 (35.6) 550 (31.8) 593 (39.9) 255 (15.7) 146 (14.1) 109 (18.7)
Yes 2072 (64.4) 1180 (68.2) 892 (60.1) 1366 (84.3) 893 (85.9) 473 (81.3)
Type of first investigation in the two years prior CRC diagnosisa <0.001 <0.001
Bowel endoscopy 1713 (53.3) 1022 (59.1) 691 (46.5) 1276 (78.7) 860 (82.8) 416 (71.5)
Abdominal/Pelvic 588 (18.3) 247 (14.3) 341 (23.0) 114 (7.0) 36 (3.5) 78 (13.4)
Non-specific
abdominal
914 (28.4) 461 (26.6) 453 (30.5) 231 (14.3) 143 (13.8) 88 (15.1)
Route to diagnosis <0.001 <0.001
Emergency
presentation
957 (29.8) 401 (23.2) 556 (37.4) 185 (11.4) 75 (7.2) 110 (18.9)
Two-week wait 1086 (33.8) 668 (38.6) 418 (28.1) 786 (48.5) 556 (53.5) 230 (39.5)
GP referral 806 (25.1) 459 (26.5) 347 (23.4) 490 (30.2) 315 (30.3) 175 (30.1)
Other in/outpatient 366 (11.4) 202 (11.7) 164 (11.0) 160 (9.9) 93 (9.0) 67 (11.5)
TNM Stage at diagnosisb 0.637 0.107
I 268 (10.6) 156 (11.2) 112 (9.9) 251 (20.4) 162 (19.8) 89 (21.8)
II 778 (30.8) 424 (30.4) 354 (31.3) 264 (21.5) 171 (20.9) 93 (22.7)
III 707 (28.0) 397 (28.4) 310 (27.4) 421 (34.3) 300 (36.6) 121 (29.6)
IV 773 (30.6) 419 (30.0) 354 (31.3) 292 (23.8) 186 (22.7) 106 (25.9)
Missing 689 (21.4) 334 (19.3) 355 (23.9) 393 (24.2) 220 (21.2) 173 (29.7)
Specific comorbidities
CVD 583 (18.1) 209 (12.9)
COPD 560 (17.4) 217 (13.4)
Diabetes 493 (15.3) 201 (12.4)
Renal disease 224 (7.0) 91 (5.6)
Comorbidity count
0 1730 (53.8) 1039 (64.1)
1 840 (26.1) 357 (22.0)
S.B. Majano et al.
5
British Journal of Cancer
the risk of emergency diagnosis (aOR= 2.9 [2.2, 3.8]) (Fig. 3 and
Supplementary Table 5).
Among rectal cancers, the proportion of emergency diagnosis
was lower, but the risk was increased by the same factors as for
colon cancer, at a comparable degree; additionally, anaemia was
also associated with emergency presentations among rectal
cancer patients (aOR= 3.5 [2.3, 5.5]) (Supplementary Table 5).
Using the Charlson score or the morbidity count consistently
indicated similar associations between morbidity burden and
emergency cancer diagnosis (Supplementary Tables 5–6).
DISCUSSION
Summary
Our findings indicate that comorbid individuals often present with
anaemia, rather than with localising symptoms, and they are less
likely promptly investigated with colonoscopy/sigmoidoscopy.
Among patients presenting to primary care with CRC-relevant
symptoms, diagnostic intervals before a cancer diagnosis are on
average more than twice as long for patients with one or more
hospital-recorded comorbidity compared to non-comorbid indivi-
duals. The risk of emergency cancer diagnosis increases with
increasing comorbidity burden and is particularly high for
individuals with CVD compared to those without.
Interpretation and comparison with the literature
The study highlighted that comorbid versus non-comorbid
patients had more frequently records of anaemia, which was
associated with a lower likelihood of prompt colonoscopy/
sigmoidoscopy and a higher risk of emergency presentation.
Previous research indicated that anaemia can be associated with
missed opportunities for earlier cancer diagnosis [42, 43]. Our
study suggests that this might particularly apply to comorbid
patients and it may partially explain their higher risk of emergency
cancer diagnosis.
Atypical symptoms are known to be associated with longer
diagnostic intervals [44, 45] and an increased risk of emergency
diagnosis [42, 46, 47], but evidence is scant on variations in
symptomatic presentations by comorbidity status and how this
might influence the timely diagnosis of cancer [11]. A previous
study indicated that colon cancer patients with ‘serious’ comor-
bidities often repeatedly presented to their doctor with cancer-
related symptoms before an emergency cancer diagnosis [22].
Research based either on primary care [13, 48] or secondary care
data [12, 49] reported longer time to cancer diagnosis for
comorbid patients [11], but to our knowledge no population-
based study has examined variations in the use and timing of
endoscopy by patients’ comorbidity status and symptoms.
Our findings indicate not only that symptomatic presentations
of CRC might differ by comorbidity status; comorbidities are also
strongly associated with a lower likelihood of prompt colono-
scopy/sigmoidoscopy and a higher risk of emergency cancer
diagnosis, independently of symptoms and socio-demographic
characteristics. This suggests that more than one mechanism
might be at play in increasing emergency presentations. Hospital-
recorded comorbidities are often complex to manage. Thus,
despite being associated with frequent healthcare encounters,
instead of providing opportunities for earlier cancer diagnosis,
they can interfere with prompt investigations of an as-yet
undiagnosed cancer [22] through the ‘competing demands’
mechanism, particularly if symptoms are vague. For instance,
severe CVD might need to be appropriately managed in some
patients before performing invasive investigations, such as
colonoscopy, which might prolong the time before cancer
diagnosis. This is in line with our finding of a lower likelihood of
prompt colonoscopy/sigmoidoscopy in patients with CVD, similar
to an American study on missed opportunities for endoscopy in
CVD patients [43]. It should be noted that shorter diagnostic
intervals might sometimes reflect rapidly progressing aggressive
cancers [50, 51]. However, our findings suggest possible
opportunities for earlier diagnosis at least in some patients with
comorbidities and cancer-related symptoms, who experienced
prolonged time before investigations.
Strengths and limitations
Strengths of the study include the use of real world population-
based data, encompassing symptomatic presentations in primary
care, hospital-recorded comorbidities, investigations performed in
hospital and ‘routes to diagnosis’ information. The study
demonstrates the usefulness of integrating clinical data spanning
across the entire diagnostic pathway. The methodology, which
has highlighted key factors to be considered for enhancing risk-
stratification and improve diagnostic timeliness, can be usefully
applied to other cancers and patient populations. It might be
particularly relevant for lung or upper GI cancers, which are often
diagnosed late and frequently present in patients with comorbid-
ities [11]. The use of validated algorithms for defining hospital-
recorded comorbidities allowed us to provide novel evidence on
the likely role played by severe morbidities in influencing the use
and timeliness of colonoscopy.
Using different morbidity markers and measures (Charlson
score, morbidity count, presence of specific morbidities)
Table 1 continued
Colon Rectum






2 384 (11.9) 127 (7.8)
3+ 261 (8.1) 98 (6.0)
Charlson Comorbidity Index (CCI) score
0 1730 (53.8) 1039 (64.1)
1 750 (23.3) 315 (19.4)
2 343 (10.7) 124 (7.6)
3+ 392 (12.2) 143 (8.8)
Total 3215 (100.0) 1730 (100.0) 1485 (100.0) 1621 (100.0) 1039 (100.0) 582 (100.0)
CIBH change in bowel habit; non red-flag symptoms include abdominal pain, constipation, diarrhoea, weight loss and fatigue; CVD cardiovascular disease,
COPD chronic obstructive pulmonary disease.
aA bowel endoscopy was performed following non-specific abdominal/pelvic tests (rather than as first test) in 11% of colon and 5% of rectal cancer patients.
bStage I–IV percentages refer to the subgroup of patients with stage information. Percentage of missing stage refers to the total sample.
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consistently indicated strong associations between morbidity
burden, longer diagnostic intervals and emergency cancer
diagnosis. Some associations might have appeared significant by
chance due to testing for multiple variables. However, the strong
evidence (p-values < 0.001) for variation by comorbidity burden in
diagnostic intervals and emergency diagnosis, suggests that such
associations are unlikely due to chance.
The study limitations include the likely underestimation of less
severe morbidities typically managed in primary care, for example,
well-controlled diabetes or benign gastro-intestinal conditions
[16, 52, 53]. Mental health issues have also not been examined
here, while they might play an important role in influencing the
timely diagnosis of cancer [44, 54]. Our study did not support the
hypothesis whereby morbidities requiring regular healthcare con-
tacts (e.g. diabetes) might provide opportunities for earlier cancer
diagnosis; nor did it support the ‘alternative explanation’mechanism
whereby morbidities with similar signs/symptoms to CRC can lead to
diagnostic delays [11, 13, 17, 44]. We cannot exclude that such
effects might apply to comorbidities managed in primary care [44].
Previous research indicated that well-controlled diabetes or
hypertension monitoring might sometimes offer opportunities for
earlier cancer diagnosis [11, 22]. Examining the role of less sever
conditions managed in primary care deserves to be examined in
detail in future studies. However, focusing on morbidities severe
enough to be recorded during a hospital admission in the 6 years
pre-diagnosis has face validity regarding the current study question,
as these morbidities may influence clinicians’ decision-making about
the use of invasive diagnostic procedures, such as colonoscopy, that
may require pre-operative assessment.
Additionally, studies based on patient interviews are needed to
evaluate patient-related factors, such as self-management of
symptoms or comorbidities, anxiety and/or willingness to undergo
invasive investigations, as these factors might also influence the
use of investigations and diagnostic timeliness. Moreover, while
we accounted for clustering of patients by GP practice, details on
area-specific availability of diagnostic services and waiting times
could provide further insights into possible reasons for longer
diagnostic intervals.
CVD and other conditions found here to be associated with
prolonged diagnostic intervals and emergency presentations are
aetiologically unrelated to CRC and they probably developed over
many years, suggesting that reverse causation unlikely explains
our findings. We did not have information on the specific event
triggering the emergency admission (bowel perforation, occlusion
or a CVD-related emergency). However, irrespective of the
triggering event, reducing emergency cancer diagnosis is a key
public health target [1, 3], as it is strongly associated with
advanced cancer stage and poor survival [7, 55].
We focused on the use of lower GI endoscopies, which are well
documented in HES. Having used routinely collected clinical
codes, ascertainment bias cannot be excluded. However, previous
validation studies have shown 96% accuracy for routine data
collected in HES [32, 33]. Imaging tests (including ultrasound
scans, CT/MRI) are only partially captured in HES, and imaging data
from HES-DID might allow to explore this further [12].
Linked data were available only up to 2015 and more recent
data is needed, considering persisting inequalities in emergency
presentations and poorer survival in comorbid patients [56, 57].
Our study does not exactly map on the primary and secondary
care intervals, as defined in other research [12, 44, 45, 50], since we
relied on the date of test performance, but lacked information on
the GP referral date. While the symptom-to-test interval in our
study is longer than the referral interval reported in a national
audit [14], it reflects the time symptomatic patients wait before
being investigated.
We lacked information on hereditary non-polyposis CRC or
familial adenomatous polyposis, but they likely represent a small
minority of cases (<2%) in our study population of mostly older
individuals.
Implications for practice and research
Lower GI endoscopy is the gold standard for investigating patients
with symptoms suggestive of CRC. Non-invasive strategies, such as
FIT or other promising tools for supporting the diagnostic process
in primary care [4–6, 58], combined with appropriate safety-
netting (including pre-booked short-term follow-up visits), can be
used for selecting patients at increased risk and referring them for
urgent investigations [59]. FIT might be particularly useful for
patients with serious comorbidities to prioritise those requiring
immediate endoscopy and reduce emergency presentations, but
risks and benefits will need to be evaluated. Older age (75 years
and over) was also significantly associated with longer diagnostic
intervals for colon cancer possibly due to the need of performing
pre-colonoscopy assessments/preparations to minimize the risks
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Fig. 2 Time intervals (days) from symptomatic primary care presentation to cancer diagnosis. Values are shown for colon (top row) and
rectal cancer (bottom row) patients by Charlson comorbidity Index (CCI) score. Solid line CCI score 0; dashed line CCI score 1; dotted line CCI
score 2; large dashed line CCI score 3+. Symptom to test and test to diagnosis intervals refer to the subgroup of patients with a relevant test
(n= 2301 colon; n= 1390 rectum), while the symptom to diagnosis intervals refer to the total sample (n= 3215 colon; n= 1621 rectum). The
symptom-to-diagnosis interval for the subgroup of tested individuals is shown Supplementary Fig. 1. Note: The median values shown here are
statistically significantly different (p < 0.001) when comparing patients with Charlson score 1+ versus 0.
S.B. Majano et al.
7




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































S.B. Majano et al.
8
British Journal of Cancer
associated with invasive investigations especially in older and frail
patients. Research is needed on appropriate testing strategies for
comorbid and older individuals and on the role played by frailty
and the risks of invasive testing in influencing clinician’s decision-
making and patient’s attitudes to testing. Using FIT and minimally
invasive radiology tests might be particularly useful as first-line
assessment in older and comorbid patients and reduce their
higher risk of emergency presentations. Timely access to cancer
diagnostic services is essential, especially for symptomatic
individuals with multimorbidity, who can be particularly vulner-
able. This has been emphasised by the recent Covid-19 crisis,
during which many cancer investigations have been postponed
with possible dramatic consequences especially for multimorbid
cancer patients [18–20, 60].
As patients with multiple conditions might not spontaneously
report all symptoms, especially if vague [61], targeted patient
education campaigns might be useful for individuals with chronic
conditions, as well as more systematic adoption of symptom
elicitation and holistic approaches during doctor-patient encounters
[62, 63]. Closer interaction and easier access to specialist advice for
GPs and use of multi-disciplinary rapid diagnostic centres might be
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Non-red flag
First investigation (Ref. Bowel endoscopy)
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No relevant investigation
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Fig. 3 Multivariable logistic regression odds ratios (OR) for the association between patient characteristics, symptoms, Charlson
comorbidity index (CCI) score, investigations and emergency cancer diagnosis (colon n= 3215; rectum n= 1621). a Colon cancer. b Rectal
cancer. CIBH change in bowel habit.
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known on how comorbidities might influence CRC screening
participation, but some studies suggested a lower screening
probability for comorbid individuals [11, 29]. Encouraging age-
based screening could be particularly valuable to reduce the risk of
emergency and advanced stage cancer diagnosis in individuals with
morbidities associated with a higher CRC risk, such as diabetes [11].
While the wider use of screening may allow diagnosing CRC earlier
and substantially reduce emergency presentations in the future,
currently only 10% of all CRC in England are diagnosed through
screening [24]. This highlights the key importance of improving the
diagnosis in symptomatic patients.’
Our findings suggest the potential usefulness of morbidity
status as a risk-stratifier when assessing the risk of diagnostic
delays in symptomatic patients with as-yet undiagnosed cancer.
For example, the positive predictive values associated with
anaemia or rectal bleeding may vary by morbidity status, given
the observed variations in symptomatic presentations. The
present research focused on CRC patients, but the methods and
findings can inform further work on other cancer sites, for
example, lung or upper GI cancers, which are often diagnosed late
and frequently present in patients with comorbidities [11, 53].
Moreover, given the greater risk among comorbid patients of
cancer being diagnosed as an emergency and at advanced stage,
our findings suggest that a lower threshold for investigations
might be beneficial, but future studies are warranted aimed at
evaluating risks and benefits of different thresholds. Research is
also warranted aimed at developing enhanced risk-stratification
tools to prioritise patients needing urgent tests, accounting for
comorbidity, symptoms and demographic characteristics.
CONCLUSIONS
The study has provided novel evidence on factors contributing to
prolonged diagnostic intervals and emergency cancer diagnosis
among the large number of cancer patients with pre-existing
morbidities. Comorbid individuals with an as-yet undiagnosed
colorectal cancer often present with anaemia, rather than with
localising symptoms, and they are less often promptly investigated
with colonoscopy/sigmoidoscopy. Our findings indicate the potential
usefulness of morbidity status, in addition to symptoms, to help
prioritize patients needing urgent tests. Enhanced risk-stratification
tools, accounting for comorbidity status, should be developed to
support clinical decision-making. While risks and benefits of different
thresholds for investigations among comorbid individuals should be
evaluated, non-invasive testing strategies, such as FIT, might be
particularly useful for patients with serious comorbidities and non-
localising symptoms to prioritise those requiring endoscopy and
reduce emergency presentations.
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